CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025

Core Insights - CARsgen Therapeutics Holdings Limited presented updated long-term follow-up results of its Phase I clinical trial for zevorcabtagene autoleucel (zevor-cel) at the 22nd International Myeloma Society Annual Meeting, highlighting its efficacy and safety in treating relapsed/refractory multiple myeloma [1][4] Efficacy - The study involved 14 patients with relapsed or refractory multiple myeloma, achieving an overall response rate of 100% with 11 patients (78.6%) reaching complete response or stringent complete response [3] - The median progression-free survival was reported at 44.1 months, while the median duration of response was 43.2 months for patients achieving complete or stringent complete response [3] - Survival rates at 24, 36, 48, and 60 months post-infusion were 100%, 92.3%, 84.6%, and 76.9%, respectively [3] Safety - No Grade 3 cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or other delayed adverse events were reported during the study [2][4] Product Information - Zevor-cel is a fully human, autologous CAR T-cell product targeting BCMA, approved by the NMPA for adult patients with relapsed/refractory multiple myeloma who have undergone at least three prior lines of therapy [5] - The product received Regenerative Medicine Advanced Therapy and Orphan Drug designations from the U.S. FDA in 2019 [5] Company Overview - CARsgen Therapeutics focuses on developing innovative CAR T-cell therapies to address unmet clinical needs across various malignancies and diseases [6] - The company has established comprehensive capabilities in CAR T-cell research and development, including target discovery, preclinical research, clinical development, and commercial-scale production [6]